Evidence map›Paper›PMID 36766961›Full record

ArticleHealthcare (Basel, Switzerland)2023

Cytokine Levels and Severity of Illness Scoring Systems to Predict Mortality in COVID-19 Infection.

Sevda Onuk, Hilal Sipahioğlu, Samet Karahan, Ali Yeşiltepe, Sibel Kuzugüden, Aycan Karabulut, Zehra Beştepe Dursun, Aynur Akın

Abstract read
In one paragraph

Article in Healthcare (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sevda OnukDepartment of Intensive Care, Kayseri City Education and Research Hospital, 38080 Kayseri, Turkey.ORCID 0000-0001-7601-1601
Hilal SipahioğluDepartment of Intensive Care, Kayseri City Education and Research Hospital, 38080 Kayseri, Turkey.
Samet KarahanDepartment of Internal Medicine, Division of Rheumatology, Kayseri City Education and Research Hospital, 38080 Kayseri, Turkey.ORCID 0000-0003-2065-4047
Ali YeşiltepeDepartment of Intensive Care, Kayseri City Education and Research Hospital, 38080 Kayseri, Turkey.
Sibel KuzugüdenDepartment of Clinical Biochemistry, Kayseri City Education and Research Hospital, 38080 Kayseri, Turkey.
Aycan KarabulutDepartment of Internal Medicine, Kayseri City Education and Research Hospital, 38080 Kayseri, Turkey.
Zehra Beştepe DursunDepartment of Infectious Disease, Kayseri City Education and Research Hospital, 38080 Kayseri, Turkey.
Aynur AkınDepartment of Medicine, Division of Anesthesiology and Reanimation Intensive Care, Erciyes University, 38039 Kayseri, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Various scoring systems and cytokines have been cited as predicting disease severity in COVID-19 infection. This study analyzed the link between mortality rate, levels of cytokines, and scoring systems such as the Glasgow Coma Scale (GCS), Acute Physiologic Assessment and Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA), and Charlson Comorbidity Index in patients infected with COVID-19. Adult patients infected with COVID-19 were followed up in the intensive care unit (ICU) and analyzed prospectively. We measured serum cytokine levels (Interleukin-10 (IL-10), Interleukin-8 (IL-8), Interleukin-6 (IL-6), Interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α) and High mobility group box 1 (HMGB-1)) and recorded GCS, APACHE II, SOFA, and Charlson comorbidity index scores on admission to the ICU. Receiver operating curve (ROC) analysis was performed to predict mortality from IL-1β, IL-6 IL-10, IL-8, TNF-α, and HMGB-1 values. Study participants were grouped as follows: Group A, survivors, and Group B, deceased, during the 28-day follow-up. The mean age was 65.69 (±13.56) in Group A (

Indexed as

APACHE IIcomorbidityCOVID-19cytokinesSARS-CoV-2Sequential Organ Failure Assessment Score

Identifiers

PMID36766961
PMCPMC9914724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.